A 8+ years journey bringing the first results. This is great news for patients and for science. Great work of the previous and current members of the TIL teams at @CCITdk and @NKI_nl
Researchers at @HerlevGentofte reported on highly efficient PD-1-targeted #CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T #celltherapy in @moltherapy Oncolytics (#MTO). https://t.co/CVVzUKEhPw